Meilleure Health International Industry Group Limited (2327) AI Stock Analysis

• Market Cap: HK$1.17B
• Dividend Yield: 2%
• Average Volume (3M): 3.52M
• Price to Earnings (P/E): 27.6
• Beta (1Y): 0.36
• Revenue Growth: -54.92%
• EPS Growth: 26.32%
• Country: HK
• Employees: 46
• Sector: Industrials
• Sector Strength: 72
• Industry: Conglomerates
• EPS (TTM): <0.01
• Shares Outstanding: 4,093,756,600
• 10 Day Avg. Volume: 6,054,000
• 30 Day Avg. Volume: 3,517,820
• PEG Ratio: -1.74
• Price to Book (P/B): 0.99
• Price to Sales (P/S): 23.42
• P/FCF Ratio: 6.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: HK$0.50 ▲(78.57% Upside)

The overall stock score is primarily influenced by the company's mixed financial performance and technical indicators. The financial performance shows significant volatility, which poses a risk. Technical analysis indicates some short-term positive momentum but lacks strong directional signals. The valuation suggests the stock may be overvalued, further impacting the score.

Positive Factors

Market Demand

The increasing global awareness of health and wellness and the trend towards preventive healthcare support long-term demand for the company's products.

Revenue Streams

Diversified revenue streams across multiple channels enhance market reach and resilience, supporting stable cash flow and growth potential.

Product Portfolio

Expanding product offerings in personal care can capture more market share and cater to evolving consumer preferences, driving long-term growth.

Negative Factors

Revenue Decline

The decline in revenue over recent years indicates potential challenges in maintaining market position and competitiveness, impacting long-term growth.

Profitability Volatility

Inconsistent profitability margins suggest operational inefficiencies and market challenges, which can hinder sustainable financial performance.

Cash Flow Instability

Unstable cash flow from operations indicates difficulties in converting earnings into cash, potentially affecting liquidity and investment capacity.

Meilleure Health International Industry Group Limited Business Overview & Revenue Model

Company Description

Meilleure Health International Industry Group Limited, an investment holding company, engages in industrial hemp, healthcare-related, trading, agency service, property investment and leasing, and property development businesses in Hong Kong, the People's Republic of China, and internationally. The company is involved in the trading of construction materials; development and sale of residential properties; property investment and leasing activities; and sale of healthcare-related products. It also provides real estate agency services; cannabidiol downstream product application services; health management services, including anti-aging, aesthetic medicine, and other health consulting; and healthcare related product sales agency services. The company was formerly known as U-Home Group Holdings Limited and changed its name to Meilleure Health International Industry Group Limited in March 2017. Meilleure Health International Industry Group Limited is headquartered in Admiralty, Hong Kong.

How the Company Makes Money

Meilleure Health generates revenue through the sale of its health products, including dietary supplements and wellness solutions, both in domestic and international markets. The company employs a multi-channel distribution strategy that includes direct sales, online platforms, and partnerships with retailers and health institutions. Additionally, Meilleure Health may engage in collaborations with other healthcare companies or research institutions to develop new products, which can lead to additional revenue streams. Their focus on innovative health solutions and expanding market presence also contributes significantly to their earnings.

Meilleure Health International Industry Group Limited Financial Statement Overview

Summary

Meilleure Health International Industry Group Limited displays a mixed financial performance with significant volatility across income, balance sheet, and cash flow metrics. While there are periods of profitability and positive cash flow, the inconsistency over the years suggests underlying operational challenges and financial instability.

Income Statement

The company has experienced significant fluctuations in revenue, with a notable decline from 2020 to 2024. Gross profit margin and net profit margin have been inconsistent, indicating volatility in profitability. The EBIT and EBITDA margins have similarly varied, pointing to operational challenges.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a reasonable level of leverage. However, the equity ratio has been decreasing, which could suggest increasing liabilities relative to assets. Return on equity has been inconsistent, reflecting variability in profitability.

Cash Flow

Cash flow from operations has been unstable, with periods of negative cash flow. Free cash flow growth has been erratic, but the company has managed to maintain positive free cash flow in recent years. The operating cash flow to net income ratio suggests some challenges in translating income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.10M	50.68M	129.30M	119.89M	253.03M	265.13M
Gross Profit	27.67M	28.91M	78.09M	66.76M	100.93M	111.25M
EBITDA	40.49M	56.52M	71.38M	55.46M	108.73M	129.38M
Net Income	39.17M	32.48M	40.83M	17.82M	60.32M	83.44M
Balance Sheet
Total Assets	1.75B	1.67B	1.70B	1.71B	1.74B	1.70B
Cash, Cash Equivalents and Short-Term Investments	9.95M	29.94M	106.31M	210.99M	380.39M	281.28M
Total Debt	345.96M	303.06M	297.06M	249.13M	170.42M	154.84M
Total Liabilities	530.15M	467.29M	442.89M	384.18M	306.35M	299.60M
Stockholders Equity	1.22B	1.20B	1.25B	1.32B	1.43B	1.40B
Cash Flow
Free Cash Flow	60.97M	188.62M	-137.32M	42.10M	-89.79M	70.39M
Operating Cash Flow	61.64M	188.75M	-136.49M	43.15M	-83.27M	70.81M
Investing Cash Flow	-94.72M	-253.98M	53.72M	-134.76M	161.56M	108.14M
Financing Cash Flow	23.96M	-6.39M	-18.90M	41.93M	-38.22M	-108.88M

Meilleure Health International Industry Group Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2327, the sentiment is Negative. The current price of 0.28 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.28, and above the 200-day MA of 0.28, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.84 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2327.

Meilleure Health International Industry Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
8162	60 Neutral	HK$447.88M	9.55	42.14%	―	-11.49%	85.40%
2327	51 Neutral	HK$1.17B	27.60	3.21%	2.00%	-54.92%	26.32%
0474	50 Neutral	HK$871.05M	-2.25	-63.64%	―	-64.04%	1.66%
0025	46 Neutral	HK$1.25B	-3.89	-3.32%	3.80%	10.38%	7.39%
2322	41 Neutral	HK$570.26M	-6.63	-12.32%	―	-26.45%	33.00%

Meilleure Health International Industry Group Limited Corporate Events

Meilleure Health to Acquire Full Control of Jiangsu Yide in Connected Deal

Meilleure Health International Industry Group Limited has agreed to acquire the entire equity interest in Jiangsu Yide from U-Home Group and individual vendor Tan Wensheng for RMB124.77 million (about HK$137 million), in a deal that will make Jiangsu Yide a wholly owned subsidiary with its financial results fully consolidated into the group’s accounts. The transaction is classified as a discloseable and connected transaction under Hong Kong listing rules because U-Home Group and Jiangsu Yide are associates of controlling shareholder and executive director Mr. Zhou, who is also providing a personal guarantee for the vendors’ obligations; as a result, the deal requires independent shareholders’ approval at a special general meeting, with a circular containing further details, independent advice and a valuation report to be sent to shareholders by 6 February 2026.

The most recent analyst rating on (HK:2327) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Meilleure Health International Industry Group Limited stock, see the HK:2327 Stock Forecast page.

Meilleure Health Appoints Joint Company Secretaries as Long-Serving Officer Resigns

Meilleure Health International Industry Group Limited has announced that its company secretary, Mr. Li Shu Pai, will resign with effect from 31 December 2025 to focus on personal commitments, with the board emphasizing that he departs without any disagreement or issues requiring shareholder attention. The company has appointed Ms. Chu Mei Yi, a seasoned company secretarial professional from Bird & Bird with extensive experience serving Hong Kong-listed firms, and Mr. Tsoi Kwai Kwan, an internal finance executive with auditing and company secretarial experience, as joint company secretaries from the same date, stating that both meet the Stock Exchange’s qualification requirements, a move that underscores the group’s focus on regulatory compliance and continuity in corporate governance.

The most recent analyst rating on (HK:2327) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Meilleure Health International Industry Group Limited stock, see the HK:2327 Stock Forecast page.

Meilleure Health Adds CEO and INED to Nomination Committee to Meet New HK Governance Rules

Meilleure Health International Industry Group Limited has appointed executive director and chief executive officer Ms. Zhou Wen Chuan and independent non-executive director Mr. Chen Shi as members of its nomination committee, effective 31 December 2025. The expanded five-member committee, which maintains a majority of independent non-executive directors and now includes representation of a different gender, is part of the company’s response to recent amendments to Hong Kong’s listing rules and corporate governance code, and is expected to enhance board diversity, strengthen governance practices and improve the effectiveness of board oversight for stakeholders.

The most recent analyst rating on (HK:2327) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Meilleure Health International Industry Group Limited stock, see the HK:2327 Stock Forecast page.

Meilleure Health Outlines Board Composition and Committee Roles

Meilleure Health International Industry Group Limited has announced the current composition of its board of directors and the allocation of roles across its four key board committees. The Board is led by co-chairmen Mr. Zhou Xuzhou and Dr. Zeng Wentao, with Ms. Zhou Wen Chuan serving as vice-chairman and chief executive officer, alongside one non-executive and three independent non-executive directors, who collectively chair and sit on the audit, remuneration, nomination and strategic committees. This updated governance structure clarifies responsibilities and oversight across core board functions, reinforcing the company’s corporate governance framework and potentially providing greater transparency and assurance to shareholders and other stakeholders.

The most recent analyst rating on (HK:2327) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Meilleure Health International Industry Group Limited stock, see the HK:2327 Stock Forecast page.